|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07H 21/04 | |
| C12N 5/12 | |||
| C07K 16/00 | |||
| A61K 39/395 | |||
| G01N 33/53 | |||
| A61K 51/10 | |||
| C07K 16/30 |
| (11) | Number of the document | 2363404 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10184938.8 |
| Date of filing the European patent application | 2002-10-23 | |
| (97) | Date of publication of the European application | 2011-09-07 |
| (45) | Date of publication and mention of the grant of the patent | 2016-09-07 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 335215 P | 2001-10-23 | US | |
| 362747 P | 2002-03-07 | US | |
| 412618 P | 2002-09-20 | US |
| (72) |
Maddon, Paul, J., US
Donovan Gerald, US
Olson, William, US
Schulke, Norbert, US
Gardner, Jason, US
Ma, Dangshe, US
|
| (73) |
Amgen Fremont Inc.,
One Amgen Center Drive, Thousand Oaks, CA 91320-1799,
US
PSMA Development Company L.L.C., One World Trade Center 47th Floor Suite J, New York, NY 10007, US |
| (54) | PSMA antibodies |
| PSMA antibodies |